Efficacy and Adverse Effects of Anlotinib+Carrilizumab+Hepatic Artery Embolization Chemotherapy for Patients with Advanced Metastatic Hepatocellular Carcinoma

Zhou Wenliang; Zhang Shixi; Guo Baoning

doi:10.3969/j.issn.1004-5775.2023.14.009

Home>Articles>Efficacy and Adverse Effects of Anlotinib+Carrilizumab+Hepatic Artery Embolization Chemotherapy for Patients with Advanced Metastatic Hepatocellular Carcinoma

DOI: 10.3969/j.issn.1004-5775.2023.14.009

Efficacy and Adverse Effects of Anlotinib+Carrilizumab+Hepatic Artery Embolization Chemotherapy for Patients with Advanced Metastatic Hepatocellular Carcinoma

Zhou Wenliang

Zhang Shixi

Guo Baoning

Keywords：AnlotinibCarlizumabTACEAdvancedMetastaticHepatocellular carcinomaEfficacyAdverse effects

Publication Date：2023-07-31

Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)

Pages：3( 1699-1701 )

HEILONG MEDICAL JOURANL

ISSN：1004-5775

Year, Vol.(Issue)：2023,47(14)